ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
ANAPTYSBIO, INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Management | $27.49M | $25.56M | – | – | $27.77M | – | – | – | – | 100.0% | – |
| Reportable Segment | – | – | $76.32M | $22.26M | $27.77M | $43.11M | $30.02M | $10.97M | $7.18M | – | – |
| Biopharma | – | $0 | – | – | $0 | – | – | – | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Management | $14.15M | $18.17M | – | – | $23.74M | – | – | – | – | – |
| Reportable Segment | – | – | $34.70M | -$26.17M | -$27.54M | -$9.67M | -$22.76M | -$40.32M | -$42.20M | – |
| Biopharma | – | -$52.81M | – | – | -$51.28M | – | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Anaptysbio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.